Trial Profile

Effect of Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Locoregionally Advanced,Low-risk Nasopharyngeal Carcinoma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Endostatin (Primary) ; Cis diamminediaquaplatinum; Cisplatin; Ropidoxuridine
Indications Nasopharyngeal cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
07 Jun 2022 Primary endpoint (5-year Overall Survival) has been met, according to a Simcere Pharmaceutical Group media release.
07 Jun 2022 According to a Simcere Pharmaceutical Group Media Release, data from this trial were presented at the 2022 annual meeting of American Society of Clinical Oncology (ASCO).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com